Tryptophan
In clinical developmentAlso known as (2S)-2-amino-3-(1H-indol-3-yl)propanoic acid, (S)-Tryptophan, (S)-alpha-Amino-beta-(3-indolyl)-propionic acid, Aminosyn 10%, Sulfite-Free+45 more
(2S)-2-amino-3-(1H-indol-3-yl)propanoic acid, (S)-Tryptophan, (S)-alpha-Amino-beta-(3-indolyl)-propionic acid, Aminosyn 10%, Sulfite-Free, Aminosyn 3.5 % M, Sulfite Free, Aminosyn 8.5 % with Electrolytes, Sulfite-Free, Aminosyn 8.5%, Sulfite-Free, Aminosyn II 10 %, Aminosyn II 15%, Aminosyn II 8.5 % with Electrolytes, Sulfite-Free, Aminosyn II 8.5 %, Sulfite-Free, Aminosyn-HBC 7 %, Sulfite-Free, Aminosyn-PF 10 %, Sulfite-Free, Aminosyn-PF 7%, Clinisol 15, Freamine III 10, Hepatamine 8, Hepatasol, L-(-)-Tryptophan, L-TRYPTOPHAN, Nephramine, Plenamine, PremaSol, ProSol, ProcalAmine 3, Restone, Somnicin, Travasol 10, Travasol 10%, Triptofano, Trophamine, Trophamine 10 %, Trophamine 6 %, Trp, W, Tryptophane, Clinimix 4.25/10, Clinimix 4.25/25, Clinimix 4.25/5, Clinimix 5/15, Clinimix 5/20, Clinimix 5/25, Clinimix E 2.75/5, Clinimix E 4.25/10, Clinimix E 4.25/5, Clinimix E 5/15, Clinimix E 5/20, Clinimix E 5/25, Tryptophanum.
Recent clinical, regulatory, research and industry developments relating to this drug.
The Effects of Kynurenine Aminotransferase Inhibition in People With Schizophrenia
Association between small intestine bacterial overgrowth and psychiatric disorders.
Restoring hippocampal glucose metabolism rescues cognition across Alzheimer's disease pathologies.
Neuroimaging of Tryptophan Challenge in People With Schizophrenia and Healthy Controls
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Neuroimaging of Tryptophan Challenge in People With Schizophrenia and Healthy Controls
Tryptophan and Behavior Therapy for Cocaine Abuse
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- International journal of molecular sciences5
- Frontiers in immunology4
- Cells2
- Microbiome2
- British journal of cancer1
- Cell communication and signaling : CCS1
- Fan Y2
- Ge Y2
- Licht TR2
- Roager HM2
- Tanaka M2
- Vécsei L2
- Wang Y2
- Agus A1
- Interdisciplinary Excellence Centre2
- National Food Institute2
- Stanford University2
- Stanford University School of Medicine2
- University of Copenhagen2
- Advanced Center for Chronic Diseases (ACCDiS)1
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 11 of the same disease areas as Tryptophan in the shared literature.
Studied across 8 of the same disease areas as Tryptophan in the shared literature.
Studied across 6 of the same disease areas as Tryptophan in the shared literature.
Studied across 5 of the same disease areas as Tryptophan in the shared literature.
Studied across 3 of the same disease areas as Tryptophan in the shared literature.
Studied across 3 of the same disease areas as Tryptophan in the shared literature.
Studied across 2 of the same disease areas as Tryptophan in the shared literature.
Studied across the same disease area as Tryptophan in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials